Results 191 to 200 of about 1,067,274 (289)

Quizartinib Resistance Mutations and Treatment Outcomes in Relapsed or Refractory FLT3‐ITD–Positive AML

open access: yesCancer Science, EarlyView.
ABSTRACT Quizartinib is a FMS‐like tyrosine kinase 3 (FLT3) inhibitor indicated for FLT3 internal tandem duplication (FLT3‐ITD)–positive acute myeloid leukemia (AML). We aimed to evaluate quizartinib resistance mechanisms, in addition to efficacy and safety outcomes, in patients with relapsed or refractory FLT3‐ITD–positive AML.
Yuichiro Semba   +21 more
wiley   +1 more source

A 3D Bioprinted Platform That Maintains the Functional Integrity of Primary AML Cells

open access: yesCell Proliferation, EarlyView.
This study presents a 3D bioprinted platform using gelatin‐hyaluronic acid hydrogels to enhance primary AML cell survival and proliferation while preserving stem‐like properties in vitro. By recapitulating in vivo‐like metabolic activity and drug resistance, this system offers a robust tool for preclinical drug screening and personalised therapy ...
Wanling Huang   +10 more
wiley   +1 more source

An Atypical Skin Presentation of Adult‐Onset Still's Disease With Histological Description: A Case Report

open access: yesJournal of Cutaneous Pathology, EarlyView.
ABSTRACT Adult‐onset Still's disease (AOSD) is an auto inflammatory disorder with a variable clinical presentation, and without a pathognomonic diagnostic test, characterized by high spiking fever, arthralgia/arthritis, a suggestive skin rash, elevated white blood cell count 10 G/L (> 80% neutrophils), elevated ferritin, with glycosylated ferritin < 20%
M. Nordmann   +7 more
wiley   +1 more source

Pure erythroid leukaemia in early infancy: Diagnostic pitfalls and clinical challenges

open access: yes
British Journal of Haematology, EarlyView.
Riccardo De Carli   +5 more
wiley   +1 more source

Simulation-based Bone Marrow Aspiration and Trephine Biopsy Education for Medical Students: A Non-randomized Controlled Trial. [PDF]

open access: yesIntern Med
Yamamoto A   +9 more
europepmc   +1 more source

Dose‐Adjusted Treatment With 7‐Day Venetoclax Plus Azacitidine or Decitabine in Patients With Acute Myeloid Leukaemia

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Acute myeloid leukaemia (AML) in older or unfit patients is commonly treated with hypomethylating agents (HMA) plus venetoclax (VEN), but prolonged VEN exposure often causes substantial haematological toxicity. We retrospectively analysed 61 elderly AML patients treated with HMA + VEN for 7 (7d), 14 (14d) or > 14 days (> 14d) per cycle.
Laurenz Steiner   +12 more
wiley   +1 more source

Autologous Bone Marrow Aspiration Concentrate (BMAC) Therapy for Primary Knee Osteoarthritis-An Observational and Dose Escalation Study. [PDF]

open access: yesIndian J Orthop
Jeyaraman M   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy